<DOC>
	<DOCNO>NCT00522236</DOCNO>
	<brief_summary>To evaluate antibody response influenza vaccine antigen administer single dose subject age 65 year</brief_summary>
	<brief_title>Safety Immunogenicity Commercially Available Influenza Vaccine ( Formulation 2007/2008 ) When Administered Elderly Subjects</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>65 year age older serious disease cancer , autoimmune disease , advance arteriosclerotic disease insulindependent diabetes mellitus , chronic obstructive pulmonary disease ( COPD ) require oxygen therapy , acute progressive hepatic disease , acute progressive renal disease , congestive heart failure bleed diathesis condition associate prolonged bleeding time hypersensitivity egg , chicken protein , chicken feather , influenza viral protein , neomycin kanamycin component vaccine history neurological symptom sign , anaphylactic shock follow administration vaccine know suspect ( high risk develop ) impairment/alteration immune function acute disease infection require systemic antibiotic antiviral therapy within past 7 day fever within past 3 day</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Adjuvanted Influenza Vaccine</keyword>
</DOC>